+

Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

Close
HomeQuizzoneWhatsappShare Flash Reads
 

Bernie Sanders is going after insulin makers over price hikes

Nov 2, 2016, 00:56 IST

Senator Bernie Sanders is going after insulin makers. 

Advertisement

On Tuesday, Sanders posted a series of tweets calling out the companies that make insulin, in particular Eli Lilly and Novo Nordisk for their "greed" and "outrageous profits."

Insulin is a hormone that helps people absorb and process the sugar in food. Roughly 1.25 million people in the US who have Type 1 diabetes need to inject insulin to live, as do some people with Type 2 diabetes, the more common form.
 
The price of Humalog, a fast-acting insulin made by Lilly, has gone up about 280% since 2006. Its competitor, Novolog, Novo Nordisk, has gone up the same amount.

Lilly's stock fell about 1.5% after he began sending the tweets.

 

Advertisement

 

Sanders also tweeted a video from his @BernieSanders handle.  

 

Andy Kiersz/Business Insider

Although the list prices have been increasing, the net price for Humalog is lower than it was in 2009, Lilly noted in  a statement emailed to Business Insider. The company also pointed to pharmacy benefit managers as part of the problem. The companies - which manage relationships between drugmakers, insurers and pharmacies - have been taking an increasing cut of drug prices.

"A permanent solution that gives everyone who uses insulin reasonable access will require leadership and cooperation across many stakeholders, including manufacturers, PBMs, payers, and policymakers," the company said. 

Advertisement

Drugmakers pay the PBMs a "rebate" to offset price increases, and for insulin, this has been rising, according to ZS Associates,  a sales and marketing firm that works in the healthcare industry.

ZS data shows that Lilly's rebate rates were 32% in 2014, and 39% in 2015. Across the industry, ZS data shows that rebates paid out to PBMs and insurers have gone up from about $40 billion four years ago to $100-$130 billion by 2016. So while list prices continue to go up, net prices to the drugmakers have stayed mostly flat.

Visit Markets Insider for constantly updated market quotes for individual stocks, ETFs, indices, commodities and currencies traded around the world. Go Now!

NOW WATCH: LIZ ANN SONDERS: The most unsettling outcome for the markets would be a surprise Trump win

Please enable Javascript to watch this video
You are subscribed to notifications!
Looks like you've blocked notifications!
Next Article